{"id":"tp-53374","type":"article-newspaper","title":"Roivant Highlights IMVT-1402 for 85,000 Difficult-to-Treat RA Patients","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/53374","datePublished":"2026-11-10T22:46:05.000Z","dateModified":"2026-11-10T22:46:05.000Z","language":"en","abstract":"Roivant estimates 85,000 people have difficult-to-treat RA. At Week 28, 92.5% of the 600-milligram group maintained an ACR20 response, compared with about 75% on placebo.","section":"Business","references":[]}